Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
Actual shortage: | 218 (6%) | |
Anticipated shortage: | 0 (0%) | |
Avoided shortage: | 10 (0%) | |
Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
To be discontinued: | 24 (7%) | |
Discontinued: | 335 (93%) | |
Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-CANDESARTAN | 32MG | TABLET | Resolved | 2020-05-13 | 2020-09-21 | 114928 |
APO-CANDESARTAN | 16MG | TABLET | Resolved | 2020-06-24 | 2021-06-14 | 118761 |
APO-CANDESARTAN | 16MG | TABLET | Resolved | 2020-06-24 | 2020-09-21 | 118763 |
APO-CANDESARTAN | 4MG | TABLET | Resolved | 2020-10-21 | 2021-03-15 | 126768 |
APO-CANDESARTAN | 32MG | TABLET | Actual shortage | 2022-03-11 | 2022-03-11 | 156534 |
APO-CANDESARTAN | 4MG | TABLET | Actual shortage | 2022-08-12 | 2022-08-12 | 166589 |
APO-CANDESARTAN | 8MG | TABLET | Actual shortage | 2022-08-12 | 2022-08-12 | 166592 |
APO-CANDESARTAN | 16MG | TABLET | Actual shortage | 2022-08-12 | 2022-08-12 | 166595 |
APO-CANDESARTAN | 16MG | TABLET | Resolved | 2021-05-14 | 2021-07-30 | 139406 |
APO-CANDESARTAN | 32MG | TABLET | Actual shortage | 2021-10-22 | 2021-10-22 | 147815 |
APO-CANDESARTAN | 16MG | TABLET | Resolved | 2017-03-11 | 2017-06-27 | 639 |
APO-CANDESARTAN | 4MG | TABLET | Resolved | 2017-03-12 | 2018-09-09 | 706 |
APO-CANDESARTAN | 32MG | TABLET | Resolved | 2017-03-20 | 2020-02-25 | 3516 |
APO-CANDESARTAN TABLETS | 16MG | TABLET | Resolved | 2025-03-20 | 2025-04-11 | 253078 |
APO-CANDESARTAN TABLETS | 8MG | TABLET | Resolved | 2025-01-30 | 2025-03-14 | 249077 |
APO-CANDESARTAN TABLETS | 16MG | TABLET | Resolved | 2024-09-20 | 2025-03-07 | 238233 |
APO-CANDESARTAN TABLETS | 4MG | TABLET | Resolved | 2024-10-04 | 2025-01-17 | 239355 |
APO-CANDESARTAN TABLETS | 4MG | TABLET | Resolved | 2024-10-04 | 2024-12-06 | 239358 |
APO-CANDESARTAN TABLETS | 16MG | TABLET | Resolved | 2024-12-12 | 2025-03-07 | 245502 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Resolved | 2017-09-07 | 2018-02-26 | 21199 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |